Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 622002 - Provider product page
- Provider
- BioLegend
- Product name
- Purified anti-Caspase-8
- Antibody type
- Monoclonal
- Antigen
- Recombinant full length human protein
- Description
- Caspase 8 (also known as ICE-like apoptotic protease 5, MORT1-associated CED-3 homolog (MACH), FADD-like ICE (FLICE), and apoptotic protease Mch-5) is a member of the peptidase family C14 that contains a death effector domain. Nine isoforms of this caspase have been reported, pro-Caspase 8 has a molecular weight of 55 kD. This caspase is found in the cytoplasm and, upon activation, in the mitochondria. Caspase 8 is the most upstream protease of caspase activation cascade, responsible for TNFRSF6/FAS/TRAIL-R mediated and TNFRSF1A induced cell death. This caspase cleaves/activates Caspase 3, Caspase 4, Caspase 6, Caspase 7, Caspase 9, Caspase 10, and Bid. Caspase 8 can be inhibited by the dominant negative isoform, ARC, and c-FLIP. Caspase 8 autocleaves into large p18 and small p10 subunits when activated by recruitment to the DISC complex at plasma membrane by FADD. This caspase interacts with FADD, CFLAR, and PEA15 proteins. Caspase 8 isoform 9 interacts at the ER with a complex containing BCAP31, BAP29, Bcl-2 and/or Bcl-2L1. Substrates for caspase 8 include androgen receptor, β-catenin, gelsolin, and vimentin. The 4-1-20 monoclonal antibody has been shown to be useful for Western blotting of human caspase 8 (55 kD pro-caspase form).
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 0.5 mg/ml
- Storage
- Upon receipt, store at 4° C.
Submitted references Stanniocalcin 1 and ovarian tumorigenesis.
Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J
Journal of the National Cancer Institute 2010 Jun 2;102(11):812-27
Journal of the National Cancer Institute 2010 Jun 2;102(11):812-27
No comments: Submit comment
No validations: Submit validation data